Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Intellia Therapeutics announces FDA acceptance of IND application for NTLA-5001 » 07:32
09/16/21
09/16
07:32
09/16/21
07:32
NTLA

Intellia Therapeutics

$150.27 /

-3.84 (-2.49%)

Intellia Therapeutics…

Intellia Therapeutics announced that the U.S. Food and Drug Administration has accepted the investigational new drug application for NTLA-5001, the company's first wholly-owned ex vivo CRISPR genome editing candidate for the treatment of cancer. NTLA-5001 is an autologous T cell receptor-T cell therapy engineered to target the Wilms' Tumor antigen for the treatment of all genetic subtypes of acute myeloid leukemia. Intellia intends to initiate patient screening by year-end in a Phase 1/2a study evaluating NTLA-5001 in adults with persistent or recurrent AML who have previously received first-line therapy. "The FDA's acceptance of our IND for NTLA-5001 is an important milestone in our pursuit of developing advanced cell therapies utilizing Intellia's proprietary engineering platform to treat patients with cancer. NTLA-5001 is our first wholly-owned ex vivo candidate to enter the clinic, and we expect to initiate this first-in-human study in adults with AML by year-end. Our treatment strategy is to leverage CRISPR/Cas9 genome editing technology to create next-generation engineered immune cells with the potential to attack cancer cells more effectively and safely than previously developed cell therapies," said Intellia President and Chief Executive Officer John Leonard, M.D. The Phase 1/2a study will evaluate the safety, tolerability, cell kinetics and anti-tumor activity of a single dose of NTLA-5001 in adults who have detectable AML after having received standard first-line therapy. The study will contain a dose escalation and expansion phase, with up to 54 participants. Once a dose is identified in each arm, two expansion cohorts will be opened for further safety assessment. In addition to the U.S., Intellia has also submitted a regulatory application to the U.K. for NTLA-5001.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$150.27 /

-3.84 (-2.49%)

NTLA Intellia Therapeutics
$150.27 /

-3.84 (-2.49%)

08/06/21 Raymond James
Intellia Therapeutics price target raised to $181 from $168 at Raymond James
08/05/21 Chardan
Intellia Therapeutics price target raised to $177 from $130 at Chardan
08/05/21 Roth Capital
Intellia Therapeutics price target raised to $180 from $110 at Roth Capital
06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
NTLA Intellia Therapeutics
$150.27 /

-3.84 (-2.49%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$150.27 /

-3.84 (-2.49%)

Over a month ago
Recommendations
Intellia Therapeutics price target raised to $181 from $168 at Raymond James » 07:58
08/06/21
08/06
07:58
08/06/21
07:58
NTLA

Intellia Therapeutics

$165.35 /

+18.12 (+12.31%)

Raymond James analyst…

Raymond James analyst Steven Seedhouse raised the firm's price target on Intellia Therapeutics to $181 from $168 and keeps an Outperform rating on the shares. Intellia is now the largest pure play gene editing company by market cap, and says the company's in vivo gene editing dataset in TTR amyloidosis surpassed even the firm's bullish expectations, the analyst tells investors in a research note.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

08/05/21 Chardan
Intellia Therapeutics price target raised to $177 from $130 at Chardan
08/05/21 Roth Capital
Intellia Therapeutics price target raised to $180 from $110 at Roth Capital
06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

Recommendations
Intellia Therapeutics price target raised to $177 from $130 at Chardan » 21:38
08/05/21
08/05
21:38
08/05/21
21:38
NTLA

Intellia Therapeutics

$165.35 /

+18.12 (+12.31%)

Chardan analyst Geulah…

Chardan analyst Geulah Livshits raised the firm's price target on Intellia Therapeutics to $177 from $130 and keeps a Buy rating on the shares post the Q2 results. Intellia announced a clinical trial application submission for its first ex vivo program, an autologous TCR T cell therapy, NTLA-5001 in acute myeloid leukemia, and expects to initiate patient screening in a Phase I study by the end of 2021, Livshits tells investors in a research note. The analyst also looks forward to additional data from the dose escalation study of its in vivo crisper gene editing program NTLA-2001 in hereditary transthyretin amyloidosis patients later this year.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

08/05/21 Roth Capital
Intellia Therapeutics price target raised to $180 from $110 at Roth Capital
06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$165.35 /

+18.12 (+12.31%)

Recommendations
Intellia Therapeutics price target raised to $180 from $110 at Roth Capital » 13:09
08/05/21
08/05
13:09
08/05/21
13:09
NTLA

Intellia Therapeutics

$166.00 /

+18.77 (+12.75%)

Roth Capital analyst Tony…

Roth Capital analyst Tony Butler raised the firm's price target on Intellia Therapeutics to $180 from $110 and keeps a Buy rating on the shares. The analyst notes that Thursday's conference call with management highlighted the clinical proof of concept and validation of the in vivo platform through the data from NTLA-2001 in transthyretin amyloidosis from June. Patients experienced a dose-dependent reduction in circulating serum TTR levels, Butler adds, pointing out that one patient at the 0.3 mg/kg dose level experienced a 96% reduction in TTR level at day 28, mean reduction was 87%. Intellia intends to achieve a 90% or greater mean reduction in TTR.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$166.00 /

+18.77 (+12.75%)

NTLA Intellia Therapeutics
$166.00 /

+18.77 (+12.75%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
NTLA Intellia Therapeutics
$166.00 /

+18.77 (+12.75%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$166.00 /

+18.77 (+12.75%)

Hot Stocks
Intellia Therapeutics expects cash to fund requirements beyond next 24 months » 07:42
08/05/21
08/05
07:42
08/05/21
07:42
NTLA

Intellia Therapeutics

$147.54 /

+8.68 (+6.25%)

Intellia expects that its…

Intellia expects that its cash, cash equivalents and marketable securities as of June 30, 2021, along with the proceeds from the July 2021 public offering of common stock, will enable the Company to fund its robust R&D plans, anticipated operating expenses and capital expenditure requirements beyond the next 24 months. This expectation excludes any strategic use of capital not currently in the Company's base-case planning assumptions.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

Earnings
Intellia Therapeutics reports Q2 EPS ($1.01), consensus (63c) » 07:42
08/05/21
08/05
07:42
08/05/21
07:42
NTLA

Intellia Therapeutics

$147.54 /

+8.68 (+6.25%)

Reports Q2 revenue $6.6M,…

Reports Q2 revenue $6.6M, consensus $11.89M. "This quarter marked an exciting new chapter for Intellia. We presented the first clinical data in history supporting precision editing of a disease-causing gene within the body following a single, systemic dose of CRISPR/Cas9. These data open a new era of medicine - one that holds the potential of curing genetic disease. The interim data from our ongoing Phase 1 trial of NTLA-2001 support its potential to halt and even reverse the relentless progression of ATTR amyloidosis with one dose. More broadly, they offer proof of concept for our LNP-based platform for systemic in vivo delivery. With these results, we believe we are unlocking the treatment of diseases that originate in the liver and introducing a rapid and reproducible development path that accelerates our in vivo portfolio," said Intellia President and Chief Executive Officer John Leonard. "In addition, together with Blackstone and Cellex, we launched a new company combining our allogeneic cell engineering platform with a clinically validated switchable, universal CAR-T construct. This new venture confers numerous benefits to Intellia, extending the reach of our technology beyond our core internal focus and giving us a meaningful stake in the company's success, even as we retain our rights across a diverse ex vivo landscape. This transaction also fortified our leading cell engineering capabilities by securing access to high-quality donor cells and dedicated manufacturing capacity to support the development of our wholly-owned ex vivo programs. We are well-positioned to build on this quarter's momentum as we close in on a number of upcoming milestones. We look forward to initiating Phase 1 trials this year for our next two candidates, NTLA-2002 for HAE and NTLA-5001 for AML. We will also share additional interim data from NTLA-2001 later this year. With a strong financial position and a well-validated platform, we intend to expand and accelerate development across our full-spectrum pipeline."

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$147.54 /

+8.68 (+6.25%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 14:55
07/15/21
07/15
14:55
07/15/21
14:55
LOGC

LogicBio Therapeutics

$3.76 /

-0.15 (-3.84%)

, SRPT

Sarepta

$67.86 /

+1.03 (+1.54%)

, NTLA

Intellia Therapeutics

$135.19 /

-5.81 (-4.12%)

, VERV

Verve Therapeutics

$47.67 /

-1.86 (-3.76%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 10:36
07/15/21
07/15
10:36
07/15/21
10:36
LOGC

LogicBio Therapeutics

$3.91 /

+ (+0.00%)

, SRPT

Sarepta

$67.30 /

+0.47 (+0.70%)

, NTLA

Intellia Therapeutics

$140.18 /

-0.82 (-0.58%)

, VERV

Verve Therapeutics

$49.02 /

-0.51 (-1.03%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

Recommendations
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler » 13:19
06/30/21
06/30
13:19
06/30/21
13:19
PSTX

Poseida Therapeutics

$9.51 /

-0.39 (-3.94%)

, NTLA

Intellia Therapeutics

$184.60 /

+32.96 (+21.74%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $17 price target on Poseida Therapeutics (PSTX), as the analyst feels the stock, which has proprietary piggyBac transposon and Cas-CLOVER gene editing technologies, is being overlooked in the aftermath of Intellia's (NTLA) in-vivo Phase 1 data on CRISPR/Cas9 therapy NTLA-2001 for the treatment of hATTR amyloidosis. Poseida has demonstrated human proof-of-concept with autologous CAR-T P-BCMA-101 in multiple myeloma and P-PSMA-101 in prostate cancer that Tenthoff believes differentiates from other CAR-T products and de-risks future allogeneic products, the analyst tells investors in a research note.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

06/23/21 Piper Sandler
Piper says 'time to take a fresh look' at Poseida after CEO meeting
05/18/21 Piper Sandler
Poseida Therapeutics transferred with Overweight rat Piper Sandler
05/17/21 BTIG
Poseida Therapeutics initiated with a Buy at BTIG
05/17/21 BTIG
Poseida Therapeutics initiated with a Buy at BTIG
NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
06/29/21 Raymond James
Intellia Therapeutics price target raised to $168 from $106 at Raymond James
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

  • 30
    Jun
  • 02
    Dec
  • 10
    Jul
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

Syndicate
Intellia Therapeutics 4.14M share Secondary priced at $145.00 » 06:11
06/30/21
06/30
06:11
06/30/21
06:11
NTLA

Intellia Therapeutics

$151.66 /

+18.46 (+13.86%)

The deal size was…

The deal size was increased to $600M from $400M and priced below last closing price of $151.61. Goldman Sachs, Jefferies, SVB Leerink and Barclays are acting as joint book running managers for the offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
06/29/21 Raymond James
Intellia Therapeutics price target raised to $168 from $106 at Raymond James
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.